Bufexamac

2 years -80 in solvent

8.9 uM [1], 8.9 uM [1], 8.9 uM [1], 8.9 uM [1], 8.9 uM [1], 8.9 uM [1]

Enzymatic deacetylation assays, The enzyme activity of purified recombinant HDAC1, HDAC2, HDAC3-NCoR and HDAC6 (1 ug of protein per well) is measured using the Active Motif HDAC Assay Kit in 96-well format following the manufacturer's instructions. Fluorescence measurements (340 nm excitation/460 nm emission) are recorded with an Analyst HT plate reader in triplicates. Each time series is performed in duplicate. For the determination of enzymatic activity in endogenous HDAC complexes, cell extract samples (375 uL each at 4 mg/mL protein concentration) are prepared from either bufexamac- or vehicle-treated HeLa cultures and are incubated with 15 ug of each antibody for 2 hours at 4 C. Subsequently, 60 uL Protein G beads equilibrated in lysis buffer containing 0.4% NP40 are added and, following incubation for 1 hour at 4 C, beads are washed twice with lysis buffer followed by 10 volumes of Assay buffer (HDAC Assay Kit). 10 uL of beads per well is added and deacetylation activity is determined as described above after 150 minutes in the absence or presence of 10 uM trichostatin A. Each point is measured in triplicate. Statistical significance is assessed by unpaired Student's t-test.

Bufexamac(Bufexamic acid) is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.

Bufexamac is a specific inhibitor of class IIB histone deacetylases.